Article citationsMore>>

R. Hehlmann, S. Saussele, M. Lauseker, P. Ulrike, E. Kovalevskaya, A. Leitner, C. Haferlach, B. Schlegelberger, M. C. Müller, B. Hanfstein, M. Pfirrmann, G. Ehninger, T. Fischer, J. Hasford, A. Hochhaus, D. K. Hossfeld, H. J. Kolb, S. W. Krause, C. Nerl, H. Pralle, A. Gratwohl, A. Tobler and H. Heimpel, “The German CML Study Group. Randomized Comparison of Imatinib 400 mg vs. Imatinib + IFN vs. Imatinib + araC vs. Imatinib after IFN vs. Imatinib 800 mg: Optimized Treatment and suRvival: Designed First Interim Analysis of the German CML Study IV [abstract],” Blood, Vol. 112, 2008. https://ash.confex.com/ash/2008/webprogram/Paper14057.html

has been cited by the following article:

Follow SCIRP
Twitter Facebook Linkedin Weibo
Contact us
+1 323-425-8868
customer@scirp.org
WhatsApp +86 18163351462(WhatsApp)
Click here to send a message to me 1655362766
Paper Publishing WeChat
Free SCIRP Newsletters
Copyright © 2006-2024 Scientific Research Publishing Inc. All Rights Reserved.
Top